Paraganglioma Market Application, Opportunity And Forecast To 2023 – Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany) and Novartis AG (Switzerland)

Scenario:

A paraganglioma or glomus tumors is a rare type of cancer occurs in a variety of places in the head and neck. The tumor begins in certain nerve cells that are distributed throughout the body. Paragangliomas affect at any age and over half of the paragangliomas appear in the temporal bone. Similar to other types of cancer, paragangliomas is very difficult to diagnose in early stages as the tumor is often slow growing and noncancerous (benign). However, it can invade other/ nearby organ and part of the body, and become cancerous and spread distantly. Though a number of diagnostic and therapeutic treatments are available in the market, none of them are that effective for the treatment and diagnostic. According to the research carried out by Florida Hospital System (2014), 1-2 patient in a million develops paragangliomas. According to cancer research the UK in 2012, globally over 14.1 million of new cancer cases were registered. The treatment for all types of cancer are nearly similar, thus, increasing prevalence of cancer has boosted the development of the new treatments. Increasing number of patients suffering from paragangliomas and continuous advances in the treatment have driven the growth of the market. Additionally, deteriorating lifestyle due to alcoholism and smoking, increasing healthcare expenditure, and increasing government support for research & development have fuelled the market growth. A number of treatment are available in the market, however, nearly all the treatment show some or other adverse effects on the body. Additionally, high cost of the treatment and side effects of the therapy may slow the growth of the market during the forecasted period.

View Reports Sample @ https://www.marketresearchfuture.com/sample_request/4838

The global paraganglioma market is expected to grow at a CAGR of ~6.1 % during the forecast period 2017-2023.

Segmentation

The global paraganglioma market is segmented on the basis of types, treatment, and end users.

On the basis of types, the market is segmented into caroid paraganglioma, cervical paraganglioma, jugular paraganglioma, secretory paraganglioma, temporal paraganglioma, vagal paraganglioma, and others.

On the basis of the treatment, the market is categorized into therapeutic treatment and diagnostic treatment. The therapeutic treatment is further segmented into surgery, embolization, and radiotherapy. The embolization is further categorized into liquid embolic agents, sclerosing agents, particulate embolic agents, and others. The radiotherapy is sub-segmented into external beam radiation therapy, brachytherapy, and unsealed source radiotherapy. The diagnostic treatments are further segmented into CT scans, MRI, angiography, blood test, and others.

On the basis of the end users, the market is segmented into hospital & clinics, ambulatory care centers, and others. 

Regional Analysis

The Americas account for the major share of the global paraganglioma market owing to the increasing prevalence of paragangliomas, well-developed technology and increasing government support for research & development. Moreover, high healthcare expenditure and changing lifestyle have fuelled the growth of the Americas paraganglioma market. The concentration of major players in this region is likely to support the growth of the market during the forecasted period.

Europe holds the second largest paraganglioma market, which is followed by Asia Pacific. Availability of the funds for research & development and strong government support have driven the market growth. Asia Pacific is the fastest growing paraganglioma market owing to the increasing prevalence of cancer, rapidly developing the economy and increasing government support.

On the other hand, the Middle East & Africa hold the least share of the market due to poor political conditions in Africa and limited availability of funds and availability of medical facilities. The Middle East dominates the Middle East & Africa Paraganglioma market due to the presence of well-developed countries like Kuwait, Qatar, Oman and South Arabia. Whereas, Africa region is expecting a healthy growth due to the presence of huge opportunity for the development of the market.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

Request Full Report @ https://www.marketresearchfuture.com/reports/paraganglioma-market-4838

Key Players in Global Paraganglioma Market

Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.),  Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K.), F. Hoffmann-La Roche Ltd. (Switzerland), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Pfizer, Inc. (U.S.), Sanofi (France), Merck & Co., Inc. (U.S.), Immunomedics (U.S.),and Oncomed Pharmaceuticals (U.S.).

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India

This release was published on openPR.